Carlos E. Orantes Appointed Chairman of hyperCORE Executive Board
“I am honored to be taking on the role of Chairman of hyperCORE, where I will continue working closely with our super network alliance partners to continue making our value proposition to Sponsors and CROs a very compelling one.” – Carlos E. Orantes, CEO of Alcanza Clinical Research
COLUMBUS, Ga. (PRWEB)
April 12, 2023
hyperCORE International has announced the appointment of Carlos E. Orantes, CEO of Alcanza Clinical Research, as Chairman of the hyperCORE Executive Leadership Board. Effective April 2023, Orantes succeeds Mark Lacy, who has served as Chairman since the super network’s inception in 2019.
“I am honored to be taking on the role of Chairman of hyperCORE, where I will continue working closely with our super network alliance partners to continue making our value proposition to Sponsors and CROs a very compelling one,” said Orantes. “The passion for delivering strong clinical research is palpable amongst all my hyperCORE colleagues, which will make this role extremely fulfilling for me both personally and professionally.”
Orantes, who has worked in drug development for almost 30 years, continues to serve as CEO of Alcanza Clinical Research. His efforts have been focused on building capable teams and leading them through transformations at several successful small to large companies, privately and publicly held. He is passionate about empowering team members and holding to a high standard of delivering on commitments.
Mark Lacy, the Founder, former CEO and Chair of hyperCORE, shared his reflections on the company’s growth and success, saying, “although it was my ‘baby’ to start, I am thrilled at the progress of hyperCORE under our outstanding leadership.” Lacy created hyperCORE in 2019, developing its original tenets, hiring key executives, and selecting partner companies. Lacy is also the Founder and CEO of Benchmark Research, a growing and dynamic network of quality clinical research sites throughout the United States that is also a founding alliance partner of hyperCORE. He also founded VaxCorps, a nationally prominent research network focusing on vaccines, of which he is the CEO. He expressed his enthusiasm for the future, stating, “I am happy and excited to remain an active member of hyperCORE.”
Lacy credits Karri Venn, CEO of hyperCORE and COO at Centricity Research, with bringing his vision to even greater heights. Venn responded in kind, stating, “it has been an absolute honor working with Mark Lacy as Chairman for the past two years. Our team at hyperCORE takes great pride in having each of its members actively supporting this wonderful clinical trial super network. Carlos Orantes is stepping into this role as one of the newer members of hyperCORE and is eager to do his part to support the continued growth and objectives we have set out for our group. I am incredibly excited to work with him and appreciate the passion he is bringing to this position.”
Share article on social media or email: